A clinical trial is currently underway in France to examine the potential of drops made from a jelly found in umbilical cords as a new treatment for sore eyes. The jelly contains cells that are believed to have the ability to repair serious damage caused by infections or injuries to the surface of the eye. The trial is focused on studying whether these drops can effectively heal chronic keratitis, which is inflammation of the cornea. This condition can arise from eye infections or wearing contact lenses for extended periods, leading to a breakdown in the cornea and increasing the risk of permanent sight loss. The trial is being carried out at six hospitals in France and aims to provide a simpler, mass-produced option for patients by utilizing the jelly drops, rather than requiring blood samples. The trial is expected to yield results later this year.
Additionally, the jelly derived from umbilical cords, known as Wharton’s Jelly, has attracted interest from researchers in various fields due to its high concentration of stem cells. These stem cells have the potential to develop into different types of organs or tissues within the body. Studies have demonstrated that injecting Wharton’s Jelly into affected joints can promote new cartilage growth, making it a promising treatment for osteoarthritis. Researchers involved in the new trial believe that the stem cells found in the jelly could stimulate the healing process in patients with keratitis that has not responded to existing treatments. The drops made from freeze-dried and sterilized Wharton’s Jelly are administered five times a day for 40 days, and the amount of healthy tissue on damaged corneas is measured to assess the efficacy of the treatment. Results are expected to be released later this year.
In conclusion, the use of drops made from Wharton’s Jelly found in umbilical cords holds potential as a new treatment for sore eyes and chronic keratitis. The ongoing clinical trial in France aims to determine the effectiveness of these drops in healing corneal inflammation. Furthermore, the abundance of stem cells in Wharton’s Jelly has piqued the interest of researchers in various medical fields, offering the potential for regenerative therapies in conditions such as osteoarthritis and diabetes. This innovative and versatile approach to treatment shows promising prospects for improving patients’ eye health and overall well-being.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
